Artivion, Inc.
Every calculator, already run for AORT
Open the full toolkit →You have the numbers on AORT. Get the argument.
A written report on which of these readings actually decide the outcome for Artivion, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
8 analysts covering AORTAnalyst Price Target Disagreement for Artivion, Inc.
Wall Street's bull case implies +108% from the current price; the bear case implies +65%. A 43% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for AORT
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Artivion, Inc.
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures; pyrolytic carbon coating services; E-vita Open NEO, a hybrid stent graft; Arcevo, an LSA hybrid stent graft system; AMDS hybrid prosthesis; and NEXUS ONE, an endovascular stent graft system. It also provides NEXUS DUO, an aortic arch system; NEXUS TRE, a custom-made three branch graft; E-vita thoracic 3G, a stent graft system; E-xtra Design Engineering, a range of stent graft systems for the treatment of aortic vascular dise…
AORT — frequently asked
Is AORT a buy right now?
Wall Street's consensus rating on Artivion, Inc. is Strong Buy across 8 analysts, with a mean price target of $42.15 (+83% vs. the current $23.04). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is AORT overvalued?
AORT trades at — trailing earnings, against a DCF fair value of $6 per share. The current price implies 25% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is AORT's next earnings date?
Artivion, Inc. is next scheduled to report earnings around Nov 5, 2026. A full AORT research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Artivion, Inc.?
Analysts covering Artivion, Inc. (AORT) range from a bear-case target of $38.00 to a bull-case high of $48.00, with a mean consensus target of $42.15 across 8 analysts. The spread of $10.00 (43% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Artivion, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Artivion, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full AORT research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Artivion, Inc., in minutes. 3 free reports included with every account — no credit card required.